FINWIRES · TerminalLIVE
FINWIRES

Hester Biosciences' Consolidated Profit Soars in Fiscal Q4; Shares Jump 10%

By

Hester Biosciences' (NSE:HESTERBIO, BOM:524669) consolidated attributable profit surged to 159.8 million Indian rupees in the fiscal fourth quarter ended March 31, from 12.9 million rupees a year ago.

Earnings per share jumped to 19.45 rupees from 1.82 rupees a year earlier, the biosciences company said in a filing to the Indian stock exchanges on Friday.

Revenue from operations in fiscal Q4 also increased to 1 billion rupees from 819.3 million rupees a year earlier.

The company's board recommended a dividend of 11 rupees per equity share of 10 rupees each for the fiscal year ended March 31.

The company's shares surged nearly 10% in recent trade.

Related Articles

Asia

Hong Kong Stocks Slide as Trump-Xi Talks Leave Investors Unimpressed; CARsgen Therapeutics Falls

Hong Kong stocks tumbled Friday after U.S. President Donald Trump departed China, with investors left underwhelmed by the outcome of his talks with Chinese President Xi Jinping in Beijing.The Hang Seng Index fell 1.6%, or 426.31 points, to close at 25,962.73, while the Hang Seng China Enterprises Index dropped 1.9%, or 167.60 points, to finish at 8,691.03.A brief U.S. summary of Thursday's talks highlighted what the White House described as a mutual commitment to reopening the Strait of Hormuz amid the conflict involving Iran.There were no signs of progress on potential sales of Nvidia's advanced H200 artificial intelligence chips to China.Trump also told Fox News that Beijing intends to purchase 200 Boeing aircraft, marking its first order for U.S.-made commercial jets in nearly a decade.Reuters reported, however, that the deal fell short of market expectations for about 500 planes.In corporate news, CARsgen Therapeutics (HKG:2171) closed over 10% lower after launching a top-up placement expected to raise about HK$462 million in net proceeds.VPower Group (HKG:1608) fell 17% after its proposed offshore debt restructuring lapsed after failing to become effective by the longstop date.

$^HSI$HKG:1608$HKG:2171
Asia

Ichigo Hotel REIT to Sell Tokyo Hotel Asset for 1.58 Billion Yen

Ichigo Hotel REIT Investment (TYO:3463) will sell its Hotel Livemax Nihombashi-Hakozaki property in Tokyo for 1.58 billion yen as part of a portfolio restructuring strategy, according to a Friday filing.The company expects to book a gain on sale of 273 million yen, which it plans to fully distribute as dividends, while using remaining proceeds for future acquisitions and value investments, it said.Ichigo Hotel REIT decided to dispose of the property due to limited growth potential because of its size and structure, it said.

$TYO:3463
Asia

Genrix Biopharma Gets Nod for for Multiple Myeloma Monotherapy Trials

Chongqing Genrix Biopharmaceutical (SHA:688443) received approval from China's National Medical Products Administration for the clinical trials of GR1803 injection, according to a Shanghai bourse filing on Friday.The drug will be tested as a monotherapy in patients with relapsed or refractory multiple myeloma.

$SHA:688443